PTO- 1478 |
Approved for use through 10/31/2024. OMB 0651-0009 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |
Serial Number: 97227807 |
Filing Date: 01/19/2022 |
Input Field |
Entered |
SERIAL NUMBER | 97227807 |
---|---|
MARK INFORMATION | |
*MARK | \\TICRS\EXPORT18\IMAGEOUT 18\972\278\97227807\xml1 \ APP0002.JPG |
SPECIAL FORM | YES |
USPTO-GENERATED IMAGE | NO |
LITERAL ELEMENT | FUJI CHEMICAL |
COLOR MARK | NO |
*DESCRIPTION OF THE MARK (and Color Location, if applicable) |
The mark consists of a circle containing alternating vertical lines that are wider at the bottom and more narrow towards the top, and next to the stylized words "Fuji Chemical". |
PIXEL COUNT ACCEPTABLE | YES |
PIXEL COUNT | 372 x 250 |
REGISTER | Principal |
APPLICANT INFORMATION | |
*OWNER OF MARK | Fuji Chemical Industries Co., Ltd. |
INTERNAL ADDRESS | 55 Yokohoonji, Kamiichi-machi |
*MAILING ADDRESS | Nakaniikawa-gun |
*CITY | Toyama Prefecture |
*COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | Japan |
*ZIP/POSTAL CODE (Required for U.S. and certain international addresses) |
9300397 |
*EMAIL ADDRESS | XXXX |
LEGAL ENTITY INFORMATION | |
TYPE | corporation |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY OF INCORPORATION | Japan |
GOODS AND/OR SERVICES AND BASIS INFORMATION | |
INTERNATIONAL CLASS | 001 |
*IDENTIFICATION | Chemical additives for use in the manufacture of pharmaceuticals and dietary supplements; active chemical ingredients for use in the manufacture of dietary supplements; active chemical ingredients for use in the manufacture of pharmaceuticals for treating cardiovascular diseases, metabolic diseases, allergies and allergy diseases, arthritis, dermatological diseases, inflammatory diseases, eye diseases, pulmonary diseases, cancer, central nervous system disorders, amyotrophic lateral sclerosis, infectious diseases, gastrointestinal diseases and urologic diseases |
FILING BASIS | SECTION 1(b) |
FILING BASIS | SECTION 44(d) |
FOREIGN APPLICATION NUMBER | 2021-159654 |
FOREIGN APPLICATION COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
Japan |
FOREIGN FILING DATE | 12/22/2021 |
INTENT TO PERFECT 44(d) |
At this time, the applicant intends to rely on Section 44(e) as a basis for registration. If ultimately the applicant does not rely on Section 44(e) as a basis for registration, a valid claim of priority may be retained. |
INTERNATIONAL CLASS | 005 |
*IDENTIFICATION | Pharmaceutical preparations for treating diseases in the nature of cardiovascular diseases, metabolic diseases, allergies and allergy diseases, arthritis, dermatological diseases, inflammatory diseases, eye diseases, pulmonary diseases, cancer, central nervous system disorders, amyotrophic lateral sclerosis, infectious diseases, gastrointestinal diseases and urologic diseases |
FILING BASIS | SECTION 1(b) |
FILING BASIS | SECTION 44(d) |
FOREIGN APPLICATION NUMBER | 2021-159654 |
FOREIGN APPLICATION COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
Japan |
FOREIGN FILING DATE | 12/22/2021 |
INTENT TO PERFECT 44(d) |
At this time, the applicant intends to rely on Section 44(e) as a basis for registration. If ultimately the applicant does not rely on Section 44(e) as a basis for registration, a valid claim of priority may be retained. |
ATTORNEY INFORMATION | |
NAME | David J. Davis |
ATTORNEY DOCKET NUMBER | 220014 |
ATTORNEY BAR MEMBERSHIP NUMBER | XXX |
YEAR OF ADMISSION | XXXX |
U.S. STATE/ COMMONWEALTH/ TERRITORY | XX |
FIRM NAME | Baker & McKenzie LLP |
INTERNAL ADDRESS | Suite 5000 |
STREET | 300 E. Randolph Street |
CITY | Chicago |
STATE | Illinois |
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | United States |
ZIP/POSTAL CODE | 60601 |
PHONE | 312-861-8019 |
FAX | 312-698-2123 |
EMAIL ADDRESS | chiusptomail@bakermckenzie.com |
OTHER APPOINTED ATTORNEY | Shima Roy, Rebecca Lederhouse, Christian Morgan and Emily Mola |
CORRESPONDENCE INFORMATION | |
NAME | David J. Davis |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE | chiusptomail@bakermckenzie.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) | david.davis@bakermckenzie.com; christian.morgan@bakermckenzie.com; meri.mclaughlin@bakermckenzie.com |
FEE INFORMATION | |
APPLICATION FILING OPTION | TEAS Standard |
NUMBER OF CLASSES | 2 |
APPLICATION FOR REGISTRATION PER CLASS | 350 |
*TOTAL FEES DUE | 700 |
*TOTAL FEES PAID | 700 |
SIGNATURE INFORMATION | |
SIGNATURE | NOT PROVIDED |
SIGNATORY'S NAME | NOT PROVIDED |
SIGNATORY'S POSITION | NOT PROVIDED |
DATE SIGNED | NOT PROVIDED |
PTO- 1478 |
Approved for use through 10/31/2024. OMB 0651-0009 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |
Serial Number: 97227807 |
Filing Date: 01/19/2022 |
The applicant's current Correspondence Information: |
David J. Davis |
PRIMARY EMAIL FOR CORRESPONDENCE: chiusptomail@bakermckenzie.com SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): david.davis@bakermckenzie.com; christian.morgan@bakermckenzie.com; meri.mclaughlin@bakermckenzie.com Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS). |
|
|